Aug 2026· International journal of pharmaceutics· Vol 702, pp.
127262
· 0 citations· 206 references
Medicine
TL;DR
This review introduces microsphere morphology, size, materials, and major fabrication techniques, including emulsion-solvent evaporation, spray drying, electrospraying, and microfluidics, and summarizes preclinical evidence on delivery routes, intramyocardial, epicardial, and intracoronary, and emphasizes design strategies.
Abstract
Myocardial infarction (MI) remains a leading cause of heart failure. Although contemporary interventions improve early survival, they fail to promote cardiac repair or prevent long-term adverse remodeling. Microspheres, with injectability, high surface-to-volume ratio, and tunable structure, have emerged as versatile therapeutic platforms and have been clinically applied in chemotherapy, hemostasis, and long-acting injectable formulations. In MI therapy, microspheres can encapsulate diverse bioactive agents, modulate the infarct microenvironment in a minimally invasive manner, and promote cardiac repair. This review introduces microsphere morphology, size, materials, and major fabrication techniques, including emulsion-solvent evaporation, spray drying, electrospraying, and microfluidics. It also summarizes preclinical evidence on delivery routes, intramyocardial, epicardial, and intracoronary, and emphasizes design strategies. Furthermore, the use of microspheres for bioactive-agent delivery, cell therapy, and three-dimensional engineered cardiac tissues is reviewed. Finally, the limitations and future perspectives of microsphere-based therapy for MI are discussed, aiming to inspire innovative strategies and accelerate clinical translation.
This review systematically analyzes the key issues facing EV-based therapeutic strategies in their progression from experimental research to clinical application, providing a practical theoretical framework for EV-based myocardial repair therapies and clarifying the prospects for EVs in the treatment of MI.
Kaiyi Zhu, Jing Bai, Liang-Fu Xu et al.· Journal of Controlled Releas...· 0 citations
Cardiovascular disease remains a major cause of morbidity and mortality worldwide, with myocardial infarction and pressure overload driving progressive cardiac injury and maladaptive remodeling that involve dynamic changes in vasculature, cells, and extracellular matrix. Current therapies do not fully prevent this proc...
Wu-Qiong Zhang, Xiao-Lin Zeng, Martin Himly et al.· Nanomedicine· 0 citations
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, and myocardial infarction (MI) frequently progresses to heart failure despite advances in contemporary therapies. A major barrier to the clinical translation of cardioprotective biologics is the lack of noninvasive, organ-targeted delivery...
Heart failure remains a major cause of global morbidity and mortality despite advances in guideline-directed medical therapy. Nanoparticle-based approaches have gained attention as strategies to enhance therapeutic delivery; however, their clinical relevance depends on addressing true pharmacological barriers rather th...
Jimmy Zhi En Heng, Z. Lee, K. Poh et al.· Circulation: Heart Failure· 0 citations
This review evaluates how extracellular vesicles, cell-derived nanovesicles, and engineered nanoparticles can be matched to these changing biological requirements to demonstrate phase-dependent target availability, controlled exposure, target-cell cargo engagement, and reduced benefit or emerging harm with a deliberate...
Myocardial ischemia-reperfusion injury (MIRI) remains a major clinical challenge associated with rapid coronary recanalization, leading to extensive irreversible cardiomyocyte loss. This process is driven by excessive oxidative stress, inflammatory responses, and impaired angiogenesis, ultimately resulting in progres...
Rui Zhang, Jin-Lu Li, Jing Dai et al.· Regenerative Biomaterials· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.